
Incorporating blinatumomab into frontline therapy for high-risk B-ALL improves MRD, survival outcomes
The authors, led by Nicolas Boissel, MD, PhD, of Hôpital Saint-Louis in Paris, France, analyzed 94 patients with high-risk B-ALL who received up to five cycles of blinatumomab during consolidation and maintenance therapy. A post hoc analysis compared outcomes in these patients with outcomes in 90 control patients treated without blinatumomab before QUEST activation.





